IDH2 R140Q (~5-9% of AML). Enasidenib (IDHIFA, AG221-C-001 Stein et al. Blood 2017) FDA-a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH2-R140Q-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH2 R140Q |
| Disease | DIS-AML |
| ESCAT tier | IA |
| Recommended combinations | enasidenib monotherapy, enasidenib + azacitidine (1L unfit, off-label/trial) |
| Evidence summary | IDH2 R140Q (~5-9% of AML). Enasidenib (IDHIFA, AG221-C-001 Stein et al. Blood 2017) FDA-approved 2017 for R/R IDH2-mut AML. IDHENTIFY (Ph3) confirmed OS benefit late-line. Combos with azacitidine (Ph2) promising 1L unfit. |
Notes
ESCAT IA. OncoKB Level 1. Differentiation syndrome AE class effect.
Used By
No reverse references found in the YAML corpus.